Newsletter

226950 - Olix Pharmaceuticals, Inc.

226950 Summary
Biopharma
Stock Price & Overview
₩99,100 +1,600 (+1.64%) Close · Sep 8, 2026 KST
KOSDAQ | ₩KRW | Close: ₩99,100  ≈ US$71  ·  Market cap ₩2.1tn (≈ $1.5bn)
Home › 226950 › Filings

Material matter affecting investment judgment (clinical trial plan applied for)

DART
Olix Pharmaceuticals, Inc.
Filed Sep 8, 2026 KST · Filing · receipt 20260908900218

kstock has not written this one up. The title above is a translation of the Korean form name; the filing itself is on DART, in Korean.

Read the original on DART ↗ Korean. DART is Korea's electronic disclosure system, run by the Financial Supervisory Service — the filing equivalent of EDGAR.
Korean form name: 투자판단관련주요경영사항(임상시험계획승인신청) (안드로겐성 탈모가 있는 건강한 남성을 대상으로 OLX72021의 안전성과 유효성을 평가하기 위한 다기관, 무작위 배정, 이중 눈가림, 위약 대조, 다중 상승 용량 제1b/2a상 임상시험 계획 승인신청)

226950

Price
₩99,100
Change
+1.64%
Market cap
₩2.1tn
Prev. close
₩97,500
226950 SummaryCompare to Peers

226950 data on kstock

Financials
11 fiscal years

Every figure is taken from Olix Pharmaceuticals, Inc.'s own DART filings and matched on IFRS account codes, so a line holds across years where the Korean wording changed.

More 226950 filings

Exercise of a conversion right on convertible shares

09/01/26

5% Ownership Report — Short Form

09/01/26

Exercise of a conversion right on convertible shares

08/31/26

Insider / Major Shareholder Holdings Report

08/28/26

Material matter affecting investment judgment

08/21/26

Half-Year Report

08/14/26
All 226950 filings